JPS60133852A - Novel natto (fermented soybean) product - Google Patents

Novel natto (fermented soybean) product

Info

Publication number
JPS60133852A
JPS60133852A JP58242126A JP24212683A JPS60133852A JP S60133852 A JPS60133852 A JP S60133852A JP 58242126 A JP58242126 A JP 58242126A JP 24212683 A JP24212683 A JP 24212683A JP S60133852 A JPS60133852 A JP S60133852A
Authority
JP
Japan
Prior art keywords
natto
product
suppressing
fermented soybean
bacteria
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP58242126A
Other languages
Japanese (ja)
Other versions
JPH0244500B2 (en
Inventor
Ryoji Sekiguchi
関口 良治
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ZENKOKU SHOKUBUTSU TANPAKU SHOKUHIN KYODO KUMIAI
Original Assignee
ZENKOKU SHOKUBUTSU TANPAKU SHOKUHIN KYODO KUMIAI
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ZENKOKU SHOKUBUTSU TANPAKU SHOKUHIN KYODO KUMIAI filed Critical ZENKOKU SHOKUBUTSU TANPAKU SHOKUHIN KYODO KUMIAI
Priority to JP58242126A priority Critical patent/JPS60133852A/en
Publication of JPS60133852A publication Critical patent/JPS60133852A/en
Publication of JPH0244500B2 publication Critical patent/JPH0244500B2/ja
Granted legal-status Critical Current

Links

Abstract

PURPOSE:To obtain a novel NATTO product good for health, containing a fructo-oligosaccharide as a component, and effective for accelerating the proliferation of bifidus bacteria in intestines, thereby suppressing the intestinal putrefaction, improving the constipation and diarrhea and suppressing the generation of ammonia. CONSTITUTION:Soybeans are boiled or steamed, added with a mixture of a suspension of Bacillus natto and fructo-oligosaccharide (preferably in an amount of 2-8g in terms of daily dose), and fermented by conventional process to obtain the objective NATTO product.

Description

【発明の詳細な説明】 本発明はフラクトオリゴ糖を含有した納豆製品に関する
DETAILED DESCRIPTION OF THE INVENTION The present invention relates to natto products containing fructooligosaccharides.

古来、納豆は我が国において広く用いられて来た食品で
あり、最近になってその植物たん白質や植物せん維から
極めて健康維持、増進に優れた食品として注目を集め、
海外でも注目されるようになって来ている。
Since ancient times, natto has been widely used in Japan, and recently it has attracted attention as a food that is extremely good for maintaining and promoting health due to its plant protein and fiber content.
It is also starting to attract attention overseas.

本発明者は、この納豆の有用性を高めるため人間の胎内
の有用菌であるビフィズス菌の繁殖を高め腐敗菌である
クロストリディウム・ベル7リンゲルス菌の繁殖を押え
ることを目的として本発明を発明した。
In order to increase the usefulness of this natto, the present inventor has invented the present invention with the aim of increasing the proliferation of Bifidobacterium, which is a useful bacterium in the human womb, and suppressing the proliferation of Clostridium bell7 Ringers, which is a putrid bacterium. invented.

即ち、本発明はフラクトオリゴ糖を含有した納豆製品に
関する。
That is, the present invention relates to natto products containing fructooligosaccharides.

本発明に用いられるフラクトオリゴ糖とは、ショ糖に7
ラクトーズが1〜3分子結合したものであって、■−ケ
トース(cyp’t )、ニスドース(GFa)、IF
−フラクトフラノシルニストーSGF番)、又はこれら
の混合物である。GF、は分子式CI+ Nu (L@
、分子量504、GFmは分子式C菅4 H4t Ot
+、分子[666、G F aは分子式C5oHsyO
宜a、分子量828である。これらフラクトオリゴ糖は
自然界では広く高等植物に分布しており、例えば7スバ
ラガス、たまねぎ、きくいもなどに含まれて無害のもの
である。これらフラクトオリゴ糖は、工業的には7スペ
ルギルス属やオーレオノ2シディウム属に分類さ−れる
糸状菌の菌体中に生産されるフラクトース転移酵素をシ
、$1に作用させることにより得られる。そして、この
糖はビフィズス菌を増殖させ、小腸内酵素等によっては
極めて分解されにく(従ってエネルギーになりにくく、
又虫歯の原因であるS、=、−タンスによる不溶性グル
カンと乳酸との生成がショ糖に比べて極めて少ないので
虫歯になりにくい性質を有する。ビフィズス菌は人間の
腸内に生育する鮪の一種であるが、周知の如く、この菌
の減少又は消失はクロストリディウム・ベル7リンゲル
スなどの腐敗菌の増加をもたらし、胎内腐敗が高まり、
7ンモ二7、硫化水素、−アミン、フェノール、インド
ールその他の有毒物質が多量に生成され、これが宿主に
吸収されて、ますまず老化を早めることになり、その上
腸内PHがアルカリ側圧傾けば腸内で生成されるアンモ
ニアの吸収が促進され、またアミノ酸脱脚酸酵素の活性
が高まり、アミンの生成が増加する。それ故人体のため
に腸内菌のバランスをビフィズス菌優勢、クロストリデ
ィウム・ベル7リンゲルスなどの有害菌劣勢とする必要
がある。フラクトオリゴ糖は前述の如く難消化性である
ため、これを摂取すると直接腸内に達し、これはビフィ
ズス菌の増殖をもたらすが一方ではクロストリディウム
・ベル7リンゲルスなどの有害菌の増殖を妨げる。この
事実は、従来ビフィズス菌増殖因子といわれてきたラク
ツロースがビフィズス菌を増殖させるが有害菌として代
表的なりpストリゾイウム・ベル7リンゲルス等にもよ
(資化されることとは対照的であって、ラクッp−スよ
り7ラクトオリゴ糖が優れているといえる。
The fructooligosaccharide used in the present invention is sucrose with 7
One to three molecules of lactose are bound together, including ■-ketose (cyp't), nisdose (GFa), and IF
-Fructofuranosylnisto SGF), or a mixture thereof. GF, has the molecular formula CI+ Nu (L@
, molecular weight 504, GFm has the molecular formula C Kan4 H4t Ot
+, molecule [666, G F a is the molecular formula C5oHsyO
The molecular weight is 828. These fructooligosaccharides are widely distributed in higher plants in the natural world, and are harmless, being contained in, for example, hexaspermica, onions, and sweet potatoes. These fructooligosaccharides are industrially obtained by reacting fructosyltransferase produced in the cells of filamentous fungi belonging to the genus Hexaspergillus and the genus Aureonosidium. This sugar causes bifidobacteria to proliferate and is extremely difficult to be broken down by enzymes in the small intestine (therefore, it is difficult to convert into energy.
In addition, since the production of insoluble glucan and lactic acid by S,=,-tance, which is the cause of dental caries, is extremely small compared to sucrose, it has the property of being less likely to cause dental caries. Bifidobacterium is a type of tuna that grows in the human intestine, and as is well known, the decrease or disappearance of this bacterium leads to an increase in putrefactive bacteria such as Clostridium ver.
7.Hydrogen sulfide, -amines, phenols, indoles, and other toxic substances are produced in large quantities, which are absorbed by the host, accelerating aging, and if the pH of the upper intestine tilts towards alkaline. The absorption of ammonia produced in the intestines is promoted, and the activity of amino acid delegating enzyme increases, increasing the production of amines. Therefore, for the sake of the human body, it is necessary to maintain a balance of intestinal bacteria in which Bifidobacterium is dominant and harmful bacteria such as Clostridium bell 7 ringers are negative. As mentioned above, fructooligosaccharides are indigestible, so when ingested, they reach the intestines directly, leading to the growth of Bifidobacteria, but on the other hand, preventing the growth of harmful bacteria such as Clostridium bell7 ringers. . This fact indicates that lactulose, which has traditionally been said to be a bifidobacteria growth factor, causes the growth of bifidobacteria, but it also causes the growth of bifidobacteria, which are representative of harmful bacteria such as P. It can be said that 7-lactooligosaccharide is superior to Lacpus.

本発明に用いられるフラクトオリゴ糖の量は、厳密を要
しないが、1日量として好ましくは1〜12を最も好ま
しくは2〜8Pである。
The amount of fructooligosaccharide used in the present invention is not strictly limited, but the daily amount is preferably 1 to 12, and most preferably 2 to 8.

本発明の納豆製品としては、従来の納豆が挙げられ例え
ば大豆それ自体、又は大豆にハトムギ、ソバ、フーン、
米、りpレラ、カルシュウム、ビーナ、ンなどを加えた
ものを原料とし、これを蒸煮し、次に納豆菌を接種し、
発酵させたものがある。
Examples of the natto product of the present invention include conventional natto, such as soybean itself, or soybean with adlay, buckwheat, hun, etc.
The raw material is rice, Riplera, calcium, beena, nug, etc., which is steamed and then inoculated with natto bacteria.
Some are fermented.

本発明の納豆製品に7ラクトオリゴ糖を加えるには、納
豆製品を製造する時のどの時点に加えてもよいが、納豆
菌を接種する際に、納豆菌液に混入して用いるのが操作
上都合が良い。
In order to add 7-lactooligosaccharides to the natto products of the present invention, they may be added at any point during the production of the natto products, but for operational reasons it is best to mix them into the natto bacteria solution when inoculating the natto bacteria. convenient.

納豆製品に7ラクトオリゴ糖を添加すると糖質であるフ
ラクトオリゴ糖が納豆[より資化されてしまうのではな
いかと思われるが、以下の実験からそのようなことは認
められなかった。
It is thought that adding 7-lactooligosaccharides to natto products may cause the fructooligosaccharides, which are carbohydrates, to be assimilated more than in natto, but this was not observed in the following experiment.

第1表 W 培地ニトリブトソイグイ冒ン培地「栄研」納豆Wi
:生菌数4.5X10”〜 75? )t リボ1w:GFt 35%+ GFm 
50L CF411%培養17’o、17時間 従って、本発明の納豆製品では、フラクトオリゴ糖はど
んな時点に添加されても納豆菌により資化されず、食用
に供することができる。
Table 1 W Medium Nitributo Soigui Incubation Medium “Eiken” Natto Wi
:Number of viable bacteria 4.5X10"~75?)t Ribo 1w: GFt 35% + GFm
50L CF4 11% culture 17'o, 17 hours Therefore, in the natto product of the present invention, fructooligosaccharide is not assimilated by Bacillus natto no matter what time it is added and can be used for food.

本発明の納豆製品は、食するとビフィズス菌の繁殖を促
進し、それにより胎内腐敗の抑制、便秘・下痢の改善な
どの人体にとり有用な作用をもたらす。
When eaten, the natto product of the present invention promotes the proliferation of bifidobacteria, thereby producing beneficial effects on the human body such as suppressing in-utero putrefaction and improving constipation and diarrhea.

フラクトオリゴ糖は、異味・異臭は全くなく、熱安定性
(140’0まで安定、メイラード反応なし)やPH安
定性(PH6以上では、120°0で安定)K優れ、納
豆製品に含有されても納豆製品の品質に悪影蕃を及ぼす
ことがない。又、毒性もなく、人体に何も影響しな(1
゜ 次に実施例を示す。
Fructooligosaccharide has no off-taste or odor, and has excellent thermal stability (stable up to 140'0, no Maillard reaction) and pH stability (stable at 120°0 at pH 6 or above), so even if it is contained in natto products. There is no negative effect on the quality of natto products. Also, it is non-toxic and has no effect on the human body (1).
゜Examples will now be shown.

実施例1 大豆60ユを秤取し、水潰して吸水させて2.2倍量と
し、これを蒸−、鬼した。
Example 1 60 units of soybeans were weighed out and crushed in water to absorb water to make 2.2 times the volume, which was then steamed and boiled.

お旋納豆菌液5俣(生菌数4.5 X 10n/d )
に、フラクトオリゴ糖(qEI35%、GFs50%、
GFal1%)4KFを加え、常法により納豆を作った
5 bags of natto bacteria solution (number of viable bacteria 4.5 x 10n/d)
, fructooligosaccharides (qEI 35%, GFs 50%,
GFal 1%) 4KF was added and natto was made by a conventional method.

出来上った納豆100を中には釣4Fの7ラクトオリゴ
糖を含有した。
The resulting natto 100 contained 7 lactooligosaccharides of Tsuri 4F.

この納豆を食べると、胎内の腐敗が抑えられ、便秘・下
痢の症状が改善された。
Eating this natto suppressed decomposition in the womb and improved symptoms of constipation and diarrhea.

特許出願人 全国植物蛋白協同組合 手続補正書(自発) 昭和59年9月、!θ日 1 事件の表示 昭和58年特許願第242126号2
、発明の名称 新規な納豆製品 3、補正をする者 事件との関係 特許出願人 トク々ヨウトプンキョクク七/ダ キ 住 所 東京都文京区千駄木2−48−8ゼンコクショ
クプノタンパクキョウドウクミ アイ塩 称 全国植物
蛋白協同組合 4、補正の対象 明細書の発明の詳細な説明の欄 5、補正の内容 (1)明細書第4ページ下から第7行と下から第8行と
の間に以下の文をそう人する。
Patent applicant: National Plant Protein Cooperative Association procedural amendment (voluntary) September 1982,! θ Day 1 Display of incident 1982 Patent Application No. 242126 2
, Title of the invention Novel natto product 3, Relationship with the case of the person making the amendment Patent applicant Tokusyoto Punkyokukuku 7/Daki Address 2-48-8 Sendagi, Bunkyo-ku, Tokyo Salt Name National Plant Protein Cooperative Association 4, Detailed explanation of the invention column 5 of the specification subject to amendment, Contents of amendment (1) Between the 7th line from the bottom and the 8th line from the bottom of page 4 of the specification Let's say the following sentences.

Claims (1)

【特許請求の範囲】[Claims] フラクトオリゴ糖を含有した納豆製品。Natto products containing fructooligosaccharides.
JP58242126A 1983-12-23 1983-12-23 Novel natto (fermented soybean) product Granted JPS60133852A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP58242126A JPS60133852A (en) 1983-12-23 1983-12-23 Novel natto (fermented soybean) product

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP58242126A JPS60133852A (en) 1983-12-23 1983-12-23 Novel natto (fermented soybean) product

Publications (2)

Publication Number Publication Date
JPS60133852A true JPS60133852A (en) 1985-07-17
JPH0244500B2 JPH0244500B2 (en) 1990-10-04

Family

ID=17084683

Family Applications (1)

Application Number Title Priority Date Filing Date
JP58242126A Granted JPS60133852A (en) 1983-12-23 1983-12-23 Novel natto (fermented soybean) product

Country Status (1)

Country Link
JP (1) JPS60133852A (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01281074A (en) * 1988-05-06 1989-11-13 Gold Kosan Kk Multiplication treatment of cell to form kneaded bond
WO1997002829A2 (en) * 1995-07-11 1997-01-30 Abbott Laboratories Use of indigestible oligosaccharides to prevent and treat diarrhea
EP1505989A2 (en) * 2002-05-20 2005-02-16 Cedars-Sinai Medical Center Manipulation of the rate of gastrointestinal transit by modulating intestinal methane concentration
WO2007043563A1 (en) * 2005-10-13 2007-04-19 Meiji Seika Kaisha, Ltd. Composition for improving intestinal flora
US9744208B2 (en) 2013-03-15 2017-08-29 Cedars-Sinai Medical Center Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens
US9845511B2 (en) 2013-03-15 2017-12-19 Cedars-Sinai Medical Center Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens
US9956292B2 (en) 2014-08-13 2018-05-01 Cedars-Sinai Medical Center Anti-methanogenic compositions and uses thereof
US10066254B2 (en) 2002-05-20 2018-09-04 Cedars-Sinai Medical Center Diagnosis of constipation by analysis of methane concentration
JP2020503034A (en) * 2016-12-27 2020-01-30 ヒルズ・ペット・ニュートリシャン・インコーポレーテッド Pet food composition and method
JP2020070245A (en) * 2018-10-30 2020-05-07 物産フードサイエンス株式会社 Agents for controlling number of ruminococcus bacteria
US10736871B2 (en) 2015-04-01 2020-08-11 Cedars-Sinai Medical Center Anti-methanogenic lovastatin analogs or derivatives and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5894363A (en) * 1981-12-01 1983-06-04 Zenkoku Shokubutsu Tanpaku Shokuhin Kyodo Kumiai Novel natto product
JPS58201980A (en) * 1982-05-19 1983-11-25 Meiji Seika Kaisha Ltd Substance for promoting propagation of lactobacillus bifidus

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5894363A (en) * 1981-12-01 1983-06-04 Zenkoku Shokubutsu Tanpaku Shokuhin Kyodo Kumiai Novel natto product
JPS58201980A (en) * 1982-05-19 1983-11-25 Meiji Seika Kaisha Ltd Substance for promoting propagation of lactobacillus bifidus

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01281074A (en) * 1988-05-06 1989-11-13 Gold Kosan Kk Multiplication treatment of cell to form kneaded bond
WO1997002829A2 (en) * 1995-07-11 1997-01-30 Abbott Laboratories Use of indigestible oligosaccharides to prevent and treat diarrhea
WO1997002829A3 (en) * 1995-07-11 1997-03-27 Abbott Lab Use of indigestible oligosaccharides to prevent and treat diarrhea
US9192618B2 (en) 2002-05-20 2015-11-24 Cedars-Sinai Medical Center Method of treating constipation-predominant irritable bowel syndrome
EP1505989A4 (en) * 2002-05-20 2007-05-09 Cedars Sinai Medical Center Manipulation of the rate of gastrointestinal transit by modulating intestinal methane concentration
EP2251017A1 (en) * 2002-05-20 2010-11-17 Cedars-Sinai Medical Center Manipulation of the rate of gastrointestinal transit by modulating intestinal methane concentration
US9066962B2 (en) 2002-05-20 2015-06-30 Cedars-Sinai Medical Center Method of using a probiotic microorganism for the treatment of diarrhea
US10066254B2 (en) 2002-05-20 2018-09-04 Cedars-Sinai Medical Center Diagnosis of constipation by analysis of methane concentration
US9358245B2 (en) 2002-05-20 2016-06-07 Cedars-Sinai Medical Center Method of treating constipation
US10844417B2 (en) 2002-05-20 2020-11-24 Cedars-Sinai Medical Center Method of distinguishing constipation predominant IBS from inflammatory bowel syndrome by analysis of methane concentration
EP1505989A2 (en) * 2002-05-20 2005-02-16 Cedars-Sinai Medical Center Manipulation of the rate of gastrointestinal transit by modulating intestinal methane concentration
WO2007043563A1 (en) * 2005-10-13 2007-04-19 Meiji Seika Kaisha, Ltd. Composition for improving intestinal flora
JPWO2007043563A1 (en) * 2005-10-13 2009-04-16 明治製菓株式会社 Composition for improving intestinal flora
US9845511B2 (en) 2013-03-15 2017-12-19 Cedars-Sinai Medical Center Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens
US10226505B2 (en) 2013-03-15 2019-03-12 Cedars-Sinai Medical Center Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens
US10519515B2 (en) 2013-03-15 2019-12-31 Cedars-Sinai Medical Center Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens
US10688149B2 (en) 2013-03-15 2020-06-23 Cedars-Sinai Medical Center Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens
US9744208B2 (en) 2013-03-15 2017-08-29 Cedars-Sinai Medical Center Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens
US9956292B2 (en) 2014-08-13 2018-05-01 Cedars-Sinai Medical Center Anti-methanogenic compositions and uses thereof
US10328151B2 (en) 2014-08-13 2019-06-25 Cedars-Sinai Medical Center Anti-methanogenic compositions and uses thereof
US10668159B2 (en) 2014-08-13 2020-06-02 Cedars-Sinai Medical Center Anti-methanogenic compositions and uses thereof
US11344501B2 (en) 2014-08-13 2022-05-31 Cedars-Sinai Medical Center Anti-methanogenic compositions and uses thereof
US10736871B2 (en) 2015-04-01 2020-08-11 Cedars-Sinai Medical Center Anti-methanogenic lovastatin analogs or derivatives and uses thereof
JP2020503034A (en) * 2016-12-27 2020-01-30 ヒルズ・ペット・ニュートリシャン・インコーポレーテッド Pet food composition and method
JP2021118741A (en) * 2016-12-27 2021-08-12 ヒルズ・ペット・ニュートリシャン・インコーポレーテッド Pet food compositions and methods for the same
JP2020070245A (en) * 2018-10-30 2020-05-07 物産フードサイエンス株式会社 Agents for controlling number of ruminococcus bacteria

Also Published As

Publication number Publication date
JPH0244500B2 (en) 1990-10-04

Similar Documents

Publication Publication Date Title
TW421673B (en) Trehalose-releasing enzyme, and its preparation and uses
JPS60133852A (en) Novel natto (fermented soybean) product
JP2005312438A (en) FOOD MATERIAL WITH HIGH gamma-AMINOBUTYRIC ACID CONTENT AND METHOD FOR PRODUCING THE SAME
JPS5953834B2 (en) Bifidobacterium growth promoter
JP2004187501A (en) Food material highly containing gamma-aminobutyric acid and method for producing the same
CN105614614B (en) A kind of active lactobacillus fermented beverage and preparation method thereof
JP2549638B2 (en) Bifidobacterium growth promoting composition
JP6955808B1 (en) How to make fermented honey
CN107041529A (en) A kind of Xinhui citrus reticulata fruit lactic acid ferment juice and preparation method thereof
CN105199939B (en) A kind of low acetic acid trimethylamine, rich in konjaku high F value oligopeptide vinegar preparation method
AU2007302899B2 (en) Pre-fermented symbiotic matrix based on a cereal suspension with encapsulated probiotics, manufacture process and corresponding utilization
JP2018082700A (en) Prebiotic composition for enhancing stability of lactobacillus strain and stability enhancement method using the same
JP2009060805A (en) New mannanase and dietary fiber food produced using the same
CN108813586A (en) A kind of weight reducing ferment generation meal packet and preparation method thereof containing small-molecular peptides and prebiotics
CN107794160A (en) A kind of corn gluten protein liquid and preparation method thereof
JP2007104906A (en) Health food
CN107198219A (en) A kind of preparation method of the food additives of the polyglutamic acid containing γ
JP2020036586A (en) Application of fermentation product by bacillus bacterium and close species thereof
JP3173805B2 (en) Fructooligosaccharide-containing syrup and method for producing the same
JP3875899B2 (en) Natto and its manufacturing method
US4278690A (en) Method of producing nutrient food by fermenting water oats with a Bacillus subtilis
JP3469881B2 (en) Method for preparing heat-resistant lactic acid bacteria Bacillus coagulans and roux containing the lactic acid bacteria
CN107518277A (en) A kind of preparation technology of wild rice ground rice
RU2262530C2 (en) Method preparing dried preparation based on bifido- and/or lactobacillus and preparation prepared by this method
CN107467448A (en) A kind of cereal beverage containing superoxide dismutase and preparation method thereof